Yuhan signed a product-supply contract to deliver active pharmaceutical ingredient (API) to a counterparty it identifies only as "a global pharmaceutical company." The contract is worth ₩131.07bn (USD 95.42m at the September 1, 2026 rate of ₩1,373.60/$1) — about 6% of Yuhan's FY2025 consolidated revenue of ₩2.19tn, a ratio the filing states directly. It runs from September 1, 2026 to May 31, 2028 (roughly 21 months), carries no advance or down payment, and the delivery region is listed as undetermined. The filing does not say what drug the API supports or disclose which company is buying it.
| Symbol | Last Price |
|---|---|
| 326030SK biopharmaceuticals Co., Ltd. | ₩86,600 +0.2% |
| 128940Hanmi Pharm. Co., Ltd. | ₩473,500 +2.8% |
| 028300HLB Co., Ltd. | ₩33,750 +2.9% |
| 298380ABL Bio Inc. | ₩71,400 +5.6% |
| 000250Samchundang Pharm | ₩157,000 +1.0% |
| 087010Peptron, Inc. | ₩157,300 +7.3% |
| 141080LigaChem Biosciences Inc. | ₩92,000 +4.2% |
| 145020Hugel, Inc. | ₩244,000 +1.5% |
| 302440SK Bioscience Co., Ltd. | ₩37,900 +0.4% |
| 009420Hanall Biopharma Co., Ltd. | ₩54,700 +1.5% |